All In Biotech

Drug Trial Radar · NCT03725722

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose Ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Applications of Delgocitinib Cream 1, 3, 8, 20 mg/g for 8 Weeks in Adult Subjects With Mild to Severe Atopic Dermatitis.

Last checked: Nov 20, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

251

Actual

Start

Dec 28, 2018

Primary completion

May 19, 2020

Study completion May 19, 2020

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Oct 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. The trial is designed to establish a dose-response signal and investigate the efficacy and safety of delgocitinib cream in the treatment of adult subjects with mild to severe atopic dermatitis (AD).

Conditions

  • Atopic Dermatitis

Interventions

  • Delgocitinib creamDrug

    Cream for topical application

  • Delgocitinib cream vehicleDrug

    The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline (Week 0) to Week 8 in Eczema Area and Severity Index (EASI) Score.Time frame: Week 0 to Week 8

Locations

31 sites in 3 countries. Site status is shown where the registry gives one.

  • Leo Pharma Investigational Site

    Birmingham, Alabama

  • Leo Pharma Investigational Site

    Encino, California

  • Leo Pharma Investigational Site

    Los Angeles, California

  • Leo Pharma Investigational Site

    Los Angeles, California

  • Leo Pharma Investigational Site

    Rolling Hills Estates, California

  • Leo Pharma Investigational Site

    Santa Ana, California

  • Leo Pharma Investigational Site

    Chicago, Illinois

  • Leo Pharma Investigational Site

    Detroit, Michigan

  • Leo Pharma Investigational Site

    New York, New York

  • Leo Pharma Investigational Site

    High Point, North Carolina

  • Leo Pharma Investigational Site

    Philadelphia, Pennsylvania

  • Leo Pharma Investigational Site

    Carlton, Australia

  • Leo Pharma Investigational Site

    Darlinghurst, Australia

  • Leo Pharma Investigational Site

    East Melbourne, Australia

  • Leo Pharma Investigational Site

    Hectorville, Australia

  • Leo Pharma Investigational Site 1

    Kogarah, Australia

  • Leo Pharma Investigational Site

    Kogarah, Australia

  • Leo Pharma Investigational Site

    Woolloongabba, Australia

  • Leo Pharma Investigational Site

    Calgary, Alberta, Canada

  • Leo Pharma Investigational Site

    Edmonton, Alberta, Canada

  • Leo Pharma Investigational Site

    Surrey, British Columbia, Canada

  • Leo Pharma Investigational Site

    Winnipeg, Manitoba, Canada

  • Leo Pharma Investigational Site

    Fredericton, New Brunswick, Canada

  • Leo Pharma Investigational Site

    Mississauga, Ontaria, Canada

  • Leo Pharma Investigational Site

    Barrie, Ontario, Canada

  • Leo Pharma Investigational Site

    Markham, Ontario, Canada

  • Leo Pharma Investigational Site

    Peterborough, Ontario, Canada

  • Leo Pharma Investigational Site

    Richmond Hill, Ontario, Canada

  • Leo Pharma Investigational Site

    Toronto, Ontario, Canada

  • Leo Pharma Investigational Site

    Toronto, Ontario, Canada

  • Leo Pharma Investigational Site

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.